Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Pancreatic cancer (PC) is a lethal malignancy with limited therapeutic options.
• Targeting DNA damage response (DDR) pathways, including ATR-CHK1 and ATM-CHK2, is a promising strategy.
• DDR alterations are common in PC, influencing treatment sensitivity.

Purpose of the Study:

• To review current literature on targeting ATR-CHK1 and ATM-CHK2 pathways in pancreatic cancer.
• To highlight preclinical evidence and clinical developments in DDR-targeted therapies for PC.
• To discuss strategies for biomarker-driven precision oncology in PC treatment.

Main Methods:

• Review of preclinical studies on ATR inhibition and its effects on replication stress, homologous recombination, and checkpoint control.
• Analysis of synergistic effects of ATR inhibitors with standard therapies (gemcitabine, FOLFIRINOX, etc.) and other DDR inhibitors (PARP, WEE1).
• Examination of genomic contexts (ATM deficiency, ARID1A alterations) influencing therapeutic sensitivity and patient stratification.
• Summary of early-phase clinical trial data for ATR inhibitors (ART0380, AZD6738, BBI-355) in PC.

Main Results:

• ATR inhibition disrupts replication stress tolerance and enhances cytotoxicity of standard PC therapies.
• Synergistic effects observed with combination therapies including PARP and WEE1 inhibitors.
• Genomic alterations like ATM deficiency and ARID1A alterations refine therapeutic sensitivity.
• Early clinical trials of ATR inhibitors show promising safety, tolerability, and preliminary efficacy in PC patients.

Conclusions:

• Targeting ATR-CHK1 and ATM-CHK2 pathways represents a viable therapeutic strategy for pancreatic cancer.
• Combination of DDR inhibitors with standard treatments or other DDR agents can enhance efficacy.
• Biomarker-driven patient stratification is crucial for optimizing precision oncology approaches in PC.
• Ongoing clinical trials of ATR inhibitors warrant further investigation for their role in PC treatment.